3-(2-6-dichloro-3-5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea and Corneal-Diseases

3-(2-6-dichloro-3-5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea has been researched along with Corneal-Diseases* in 1 studies

Trials

1 trial(s) available for 3-(2-6-dichloro-3-5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea and Corneal-Diseases

ArticleYear
Ocular Adverse Effects of Infigratinib, a New Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibitor.
    Ophthalmology, 2021, Volume: 128, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Corneal Diseases; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Osteomalacia; Paraneoplastic Syndromes; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 1

2021